SEATTLE, Wash. and VANCOUVER, British Columbia, April 3, 2019 /PRNewswire/ -- Achieve
Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation, today announced that
Rick Stewart, Chairman and Chief
Executive Officer, will present at HC Wainwright Global Life
Sciences Conference being held at the Grosvenor House in
Mayfair, London on Monday, April
8 at 11:50 a.m. BST.
A live webcast of the presentation can be accessed at
http://ir.achievelifesciences.com/events-and-webcasts. A replay of
the webcast will also be archived on Achieve's website following
the conference.
About Achieve
Tobacco use is currently the
leading cause of preventable death and is responsible for nearly
seven million deaths annually worldwide1. It is
estimated that 28.7% of cancer deaths in the U.S. are attributable
to cigarette smoking2.
Achieve's focus is to address the global smoking health epidemic
through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Achieve Contact
Jason
Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1World Health Organization. WHO Report on the Global
Tobacco Epidemic, 2017. Geneva:
World Health Organization, 2017
2Annals of Epidemiology , Volume 25 , Issue 3 , 179 -
182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-present-at-hc-wainwright-global-life-sciences-conference-on-april-8-2019-300820838.html
SOURCE Achieve Life Sciences, Inc.